Asset Details
Do you wish to reserve the book?
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer
Do you wish to request the book?
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer
2013
Overview
Globo H (GH) is a hexasaccharide specifically overexpressed on a variety of cancer cells and therefore, a good candidate for cancer vaccine development. To identify the optimal carrier and adjuvant combination, we chemically synthesized and linked GH to a carrier protein, including keyhole limpet hemocyanion, diphtheria toxoid cross-reactive material (CRM) 197 (DT), tetanus toxoid, and BSA, and combined with an adjuvant, and it was administered to mice for the study of immune response. Glycan microarray analysis of the antiserum obtained indicated that the combination of GH-DT adjuvanted with the α-galactosylceramide C34 has the highest enhancement of anti-GH IgG. Compared with the phase III clinical trial vaccine, GH–keyhole limpet hemocyanion/QS21, the GH-DT/C34 vaccine elicited more IgG antibodies, which are more selective for GH and the GH-related epitopes, stage-specific embryonic antigen 3 (SSEA3) and SSEA4, all of which were specifically overexpressed on breast cancer cells and breast cancer stem cells with SSEA4 at the highest level (>90%). We, therefore, further developed SSEA4-DT/C34 as a vaccine candidate, and after immunization, it was found that the elicited antibodies are also IgG-dominant and very specific for SSEA4.
Publisher
National Academy of Sciences,National Acad Sciences
Subject
/ Animals
/ Antigens
/ Antigens, Tumor-Associated, Carbohydrate - administration & dosage
/ Antigens, Tumor-Associated, Carbohydrate - chemistry
/ Antigens, Tumor-Associated, Carbohydrate - immunology
/ Antigens, Tumor-Associated, Carbohydrate - pharmacology
/ Bacterial Proteins - immunology
/ Breast Neoplasms - immunology
/ Breast Neoplasms - prevention & control
/ Epitopes
/ Female
/ Immunoglobulin G - immunology
/ Mice
/ Neoplastic Stem Cells - metabolism
/ Proteins
/ Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
/ Stage-Specific Embryonic Antigens - immunology
/ tetanus
/ Vaccines
